COMMUNIQUÉS West-GlobeNewswire

GLUCOTRACK ANNOUNCES 90-DAY PRECLINICAL STUDY RESULTS THAT DEMONSTRATE SUSTAINED ACCURACY OF ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR
05/06/2024
Highly accurate continuous blood glucose monitor demonstrates Mean Absolute Relative Difference (MARD) of 4.7% at Day 90 Continuous blood glucose monitor offers the potential for simplified, discreet and less intrusive [...]
Sharps Technology Secures SC Asset Purchase Exclusivity with $1 Million Escrow Deposit
05/06/2024
InjectEZ acquisition establishing Sharps position in the prefillable syringe (PFS) industry in the U.S. has progressed with the payment of $1 million into third-party escrow account. Closing on the Asset Purchase and [...]
Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
05/06/2024
Study intended to optimize design elements needed for the upcoming US Pivotal Phase 3 studies and support ongoing partnership discussions Topline results expected in early Q4 2024 GLEN ALLEN, Va., June 05, 2024 (GLOBE [...]
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
05/06/2024
- Company positioning multiple assets for late-stage development across its therapeutic pipeline – BOSTON and ATLANTA, June 05, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company [...]
Nanox Launches Artificial Intelligence Functionality in Second Opinions Platform
05/06/2024
Nanox integrates FDA-cleared population health AI solutions into its Second Opinions service New AI capabilities a vailable to patients who submit chest and abdominal CT scans for second opinions Offering the power of [...]
Carrick Therapeutics Establishes New Headquarters in Boston, Massachusetts
05/06/2024
Appoints David Sutherland, CPA, as Vice President of Finance and Controller BOSTON, June 05, 2024 (GLOBE NEWSWIRE) -- Carrick Therapeutics Inc., an oncology-focused biopharmaceutical company discovering and developing [...]
Dr. Michael Dent Finances $1 Million to Drive HealthLynked's Healthcare Transformation
05/06/2024
Naples, FL, June 05, 2024 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp ( OTCQB: HLYK ), a leader in personalized healthcare and patient-centric services, proudly announces a $1 million financing by its CEO, Dr. [...]
Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
05/06/2024
CONSHOHOCKEN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the Goldman Sachs 45 th Annual Global Healthcare Conference on [...]
Clene to Present at the Emerging Growth Conference
05/06/2024
SALT LAKE CITY, June 05, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company [...]
Equip’s Second Annual Report Highlights First-Rate Patient Outcomes, Company Growth
05/06/2024
Available to more than 110 million Americans of all ages, Equip’s wraparound program meets patients at every stage of treatment SAN DIEGO, June 05, 2024 (GLOBE NEWSWIRE) -- Equip , the leading provider of virtual, [...]
Bluejay Therapeutics Presents Positive Preliminary BJT-778 Data from Phase 2 Clinical Trial in Chronic Hepatitis D at EASL 2024 Congress
05/06/2024
100% of treated patients in Arm 1 achieved virologic response by Week 28 Most patients also achieved ALT normalization and composite response BJT-778 was well tolerated across all arms at doses up to 900mg SAN MATEO, [...]
GeneType and Stayhealthy Announce Landmark Distribution Agreement for Revolutionary Multi-Risk Test
05/06/2024
MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, and [...]
Astiva Health Summer Gala: An Inaugural Celebration
05/06/2024
ORANGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- via IBN -- Astiva Health Inc., a fast-growing Medicare Advantage Prescription Drug (MAPD) health plan dedicated to reshaping personalized and comprehensive healthcare, [...]
VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201
05/06/2024
Trial will evaluate once-daily VYN201 gel in subjects with either active or stable nonsegmental vitiligo Top-line data from the 24-week double-blind portion of the trial expected in mid-2025 BRIDGEWATER, N.J., June 05, [...]
Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024
05/06/2024
-- Poster highlights promising preclinical profile of ABI-6250 ahead of entry into the clinic, expected by end of 2024 -- SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq [...]
Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2024
05/06/2024
Presentation to highlight statistically significant Phase 3 results of Tonmya™ (TNX-102 SL) for the management of fibromyalgia New Drug Application (NDA) submission to the FDA on track for the second half of 2024 [...]
Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer
05/06/2024
Oak Ridge, TN, June 05, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the appointment of Dr. John L. Jefferies, M.D., M.B.A., M.P.H [...]
Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
05/06/2024
New long-term safety and efficacy data of investigational roflumilast cream 0.15% in mild to moderate atopic dermatitis will be presented in an oral session Preclinical data on ARQ-234, CD200R agonist, for the treatment [...]
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
05/06/2024
MALVERN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative [...]

Pages